Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The leading academic who has overseen the expansion of world-leading medical research at the NIHR Oxford Biomedical Research Centre (BRC) for the past nine years is stepping down. Professor Keith Channon will be replaced as Director of the Oxford BRC by Professor Helen McShane, a leading vaccine specialist.

Helen McShane for web.jpg

Professor Helen McShane

Prof Channon was appointed to lead the BRC, one of the National Institute of Health Research’s largest research centres, in 2009. He has overseen two successful bids for government funding to carry out research that benefits NHS patients: for £95.5m in 2012; and £113.7m for the period from 2017 to 2022, to support research across 20 medical themes.

The NIHR Oxford BRC is based at Oxford University Hospitals (OUH) NHS Foundation Trust and run in partnership with the University of Oxford.

Find out more (Oxford BRC website)

Similar stories

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.

RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Major new study could help protect millions of people with type 2 diabetes from cardiovascular disease

A new study led by the Nuffield Department of Population Health at the University of Oxford will research whether a daily tablet could help protect the millions of people worldwide with type 2 diabetes from developing cardiovascular disease.

Professor Susan Jebb appointed as Chair of the Food Standards Agency

Susan Jebb, Professor of Diet and Population Health in Oxford University’s Nuffield Department of Primary Care Health Sciences, has been appointed as the new Chair of the Food Standards Agency.